Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158732 | 1.00 | CHRNA7 (0.47) | CHRNA7HTR3EHTR3BALOX15TSHR | |
| SCHEMBL13801613 | 0.87 | USP30 (0.49) | CHRNA7HTR3EHTR3BALOX15TSHR | |
| SCHEMBL13814721 | 0.87 | USP30 (0.49) | CHRNA7HTR3EHTR3BALOX15TSHR | |
| SCHEMBL4149855 | 0.86 | TSHR (0.44) | CHRNA7HTR3EHTR3BALOX15TSHR | |
| SCHEMBL4149852 | 0.86 | TSHR (0.44) | CHRNA7HTR3EHTR3BALOX15TSHR | |
| SCHEMBL4144599 | 0.85 | SPTLC2 (0.53) | CHRNA7HTR3EHTR3BALOX15TSHR | |
| SCHEMBL4144597 | 0.85 | SPTLC2 (0.53) | CHRNA7HTR3EHTR3BALOX15TSHR | |
| SCHEMBL4149396 | 0.82 | CHRNA7 (0.49) | CHRNA7HTR3EHTR3BALOX15TSHR | |
| SCHEMBL4124206 | 0.82 | CHRNA7 (0.49) | CHRNA7HTR3EHTR3BALOX15TSHR | |
| SCHEMBL4146444 | 0.82 | TACR1 (0.46) | DRD2DRD4SPTLC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | CHRNA7 539/4885HTR3E 215/4885HTR3B 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.